Our patients may have already lost the battle for additional evidence to help tailor optimal risks and benefits with ischemic stroke. We can, however, help ensure added protections for future innovations by taking a more active but cautious role in the process of translating external guidance to the emergency department.
Explore This IssueACEP Now: Vol 37 – No 06 – June 2018
Dr. Radecki is assistant professor of emergency medicine at The University of Texas Medical School at Houston. He blogs at Emergency Medicine Literature of Note and can be found on Twitter @emlitofnote.
- Kolata G. For many strokes, there’s an effective treatment. Why aren’t some doctors offering it? The New York Times. March 26, 2018, p. D1.
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995; 333(24):1581-1587.
- Prasad V, Vandross A, Toomey C, et al. A decade of reversal: an analysis of 146 contradicted medical practices. Mayo Clin Proc. 2013;88(8):790-798.